(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea...
Stats | |
---|---|
今日成交量 | 140.16M |
平均成交量 | 65.93M |
市值 | 87.84M |
EPS | $0 ( 2024-04-01 ) |
下一个收益日期 | ( $0 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.180 |
ATR14 | $0.00200 (0.63%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Chaturvedi Pravin R | Buy | 134 | Common Stock |
2024-04-05 | Chaturvedi Pravin R | Sell | 134 | Restricted stock units |
2024-04-05 | Wolin Jonathan S. | Buy | 89 | Common Stock |
2024-04-05 | Wolin Jonathan S. | Sell | 89 | Restricted stock units |
2024-04-05 | Lizak Carol R. | Buy | 60 | Common Stock |
INSIDER POWER |
---|
80.70 |
Last 99 transactions |
Buy: 3 516 210 | Sell: 493 473 |
音量 相关性
Jaguar Health Inc 相关性 - 货币/商品
Jaguar Health Inc 财务报表
Annual | 2023 |
营收: | $9.76M |
毛利润: | $5.34M (54.67 %) |
EPS: | $-1.790 |
FY | 2023 |
营收: | $9.76M |
毛利润: | $5.34M (54.67 %) |
EPS: | $-1.790 |
FY | 2022 |
营收: | $11.96M |
毛利润: | $9.94M (83.11 %) |
EPS: | $-36.18 |
FY | 2021 |
营收: | $4.34M |
毛利润: | $2.00M (46.18 %) |
EPS: | $-294.27 |
Financial Reports:
No articles found.
Jaguar Health Inc
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。